Leyla Sahratova
Research Subjects
Leyla Sahratova has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Fatma Gül Demirkan
Department of Pediatric Rheumatology Health Sciences University, Kanuni Sultan Süleyman Training and Research Hospital İstanbul Türkiye
2 shared publications - Govhar Verdiyeva
Department of Pediatrics, Educational Therapeutic Clinic of Azerbaijan Medical University, Baku, Azerbaijan
2 shared publications - Vafa Guliyeva
Department of Pediatric Rheumatology, Istanbul University Istanbul Faculty of Medicine , Istanbul
2 shared publications - Agharza Aghayev
Department of Genetics, Institute of Health Sciences, Istanbul University
1 shared publication - Anar Tagiyev
Department of Pediatric Gastroenterology, Leyla Medical Clinic , Baku, Azerbaijan
1 shared publication - Aslihan Seda Dagdemir
Department of Medical Genetics, Referans Clinical Laboratory Center , Baku, Azerbaijan
1 shared publication
Latest Publications
- Open Access
- 11 September 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (10)
Familial Mediterranean fever in Azerbaijani children: a nationwide cohort study of genotype–phenotype association
Objectives: Familial Mediterranean fever (FMF) is highly prevalent in Mediterranean populations, yet data from Azerbaijan remain scarce despite its location within the traditional FMF belt. This study presents the first nationwide characterization of paediatric FMF in Azerbaijan. Methods: A multicentre retrospective cohort study was conducted across paediatric and genetic referral centres in 11 regions of Azerbaijan. Demographic, clinical and genetic data were analysed. Genotype–phenotype associations were evaluated, with particular emphasis on the distribution of variants across exons and the allelic burden of exon 10 variants. Results: A total of 349 paediatric patients (60.45% boys) were enrolled. The median age at symptom onset and diagnosis was 4 (0–18) and 7 (0–23) years, respectively. The most prevalent MEFV variants were M694V (47.3%), V726A (20.1%) and R202Q (19.8%). Zygosity distribution was 18.3% homozygous, 40% heterozygous and 41.5% compound heterozygous. Genotype–phenotype analyses included 329 patients after excluding isolated R202Q heterozygotes. Fever (79.3%) and abdominal pain (66.6%) were the most frequent manifestations. Compound heterozygous exon 10 genotypes were associated with earlier symptom onset in univariate analyses. In multivariable hierarchical logistic regression analyses, the presence of at least one M694V allele independently increased the likelihood of early-onset disease (odds ratio 2.10; 95% CI: 1.29, 3.43; P = 0.003), while the zygosity-based model supported an association between biallelic exon 10 involvement and early disease onset. Conclusion: This first nationwide paediatric FMF study from Azerbaijan reveals substantial regional genetic heterogeneity, with compound heterozygosity associated with earlier disease onset. These findings advance FMF epidemiology in the Caucasus and support improved genetic counselling and surveillance for high-risk genotypes.
- 11 September 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (10)
Open AccessFamilial Mediterranean fever in Azerbaijani children: a nationwide cohort study of genotype–phenotype association
Objectives: Familial Mediterranean fever (FMF) is highly prevalent in Mediterranean populations, yet data from Azerbaijan remain scarce despite its location within the traditional FMF belt. This study presents the first nationwide characterization of paediatric FMF in Azerbaijan. Methods: A multicentre retrospective cohort study was conducted across paediatric and genetic referral centres in 11 regions of Azerbaijan. Demographic, clinical and genetic data were analysed. Genotype–phenotype associations were evaluated, with particular emphasis on the distribution of variants across exons and the allelic burden of exon 10 variants. Results: A total of 349 paediatric patients (60.45% boys) were enrolled. The median age at symptom onset and diagnosis was 4 (0–18) and 7 (0–23) years, respectively. The most prevalent MEFV variants were M694V (47.3%), V726A (20.1%) and R202Q (19.8%). Zygosity distribution was 18.3% homozygous, 40% heterozygous and 41.5% compound heterozygous. Genotype–phenotype analyses included 329 patients after excluding isolated R202Q heterozygotes. Fever (79.3%) and abdominal pain (66.6%) were the most frequent manifestations. Compound heterozygous exon 10 genotypes were associated with earlier symptom onset in univariate analyses. In multivariable hierarchical logistic regression analyses, the presence of at least one M694V allele independently increased the likelihood of early-onset disease (odds ratio 2.10; 95% CI: 1.29, 3.43; P = 0.003), while the zygosity-based model supported an association between biallelic exon 10 involvement and early disease onset. Conclusion: This first nationwide paediatric FMF study from Azerbaijan reveals substantial regional genetic heterogeneity, with compound heterozygosity associated with earlier disease onset. These findings advance FMF epidemiology in the Caucasus and support improved genetic counselling and surveillance for high-risk genotypes.
- Open Access
- 31 August 2026
- Published by Hacettepe University Institute of Child Health in The Turkish Journal of Pediatrics
- Vol. 68 (4) , 1-12
Genotype–phenotype divergence in pediatric familial Mediterranean fever across two closely related populations: a Türkiye–Azerbaijan comparison
Background. Familial Mediterranean fever (FMF) is the most common monogenic autoinflammatory disease and has a high prevalence in Türkiye. Despite shared ethnic ties, pediatric FMF in Azerbaijan remains poorly characterized. This study aimed to systematically compare the clinical, laboratory, and genetic characteristics of pediatric FMF patients from Türkiye and Azerbaijan to determine whether common ancestral origins result in uniform disease expression. Methods. This retrospective bicentric study enrolled pediatric FMF patients aged 0–18 years who met the Eurofever/PRINTO criteria and had ≥12 months of follow-up at specialized centers in Türkiye and Azerbaijan. Demographics, clinical features, laboratory findings, Mediterranean FeVer (MEFV) genotypes, severity scores, and treatment data were compared. Results. The cohort comprised 549 patients: 477 (86.9%) Turkish and 72 (13.1%) Azerbaijani. Azerbaijani patients had earlier symptom onset (30 [IQR 16-67] vs. 48 [IQR: 24–72] months, p=0.044) but a longer diagnostic delay (14 [IQR: 11.4–48.7] vs. 12 [IQR: 6–23] months, p<0.001). Turkish patients showed higher rates of chest pain (22.6% vs. 8.3%, p=0.005), arthralgia (52.6% vs. 32 %, p= 0.001), annual attack frequency (12 [IQR: 6–12] vs. 6 [IQR: 4–8], p<0.001), International Severity Score for Familial Mediterranean Fever (ISSF) scores (2 [IQR: 1–3] vs. 2 [IQR: 1–2], p=0.002), and C-reactive protein (CRP) levels (56 [IQR: 34–96] vs. 17.9 [IQR: 3.2–35.6] mg/L, p<0.001). Confirmatory exon 10 genotypes predominated in Turkish patients (66.7%) whereas unconfirmatory genotypes in Azerbaijani patients (59.7%). M694V was the most common variant in both groups. Within exon 10 homozygotes, Turkish patients had higher ISSF scores (median 3 [IQR: 2–4] vs. 2 [IQR: 1–3], p=0.037) and more arthritis (39% vs 6.3%, p=0.032). Colchicine response was comparable (90.6% vs. 93.1%), but anti–IL-1 use was higher in Turkish patients (11.5% vs. 2.9%, p=0.028). Conclusion. This first systematic Türkiye–Azerbaijan comparison reveals distinct genotype–phenotype correlations in pediatric FMF, with Turkish patients showing a higher burden of confirmatory exon 10 genotypes and more severe disease, highlighting the need for center- and population-aware management strategies.
- 31 August 2026
- Published by Hacettepe University Institute of Child Health in The Turkish Journal of Pediatrics
- Vol. 68 (4) , 1-12
Open AccessGenotype–phenotype divergence in pediatric familial Mediterranean fever across two closely related populations: a Türkiye–Azerbaijan comparison
Background. Familial Mediterranean fever (FMF) is the most common monogenic autoinflammatory disease and has a high prevalence in Türkiye. Despite shared ethnic ties, pediatric FMF in Azerbaijan remains poorly characterized. This study aimed to systematically compare the clinical, laboratory, and genetic characteristics of pediatric FMF patients from Türkiye and Azerbaijan to determine whether common ancestral origins result in uniform disease expression. Methods. This retrospective bicentric study enrolled pediatric FMF patients aged 0–18 years who met the Eurofever/PRINTO criteria and had ≥12 months of follow-up at specialized centers in Türkiye and Azerbaijan. Demographics, clinical features, laboratory findings, Mediterranean FeVer (MEFV) genotypes, severity scores, and treatment data were compared. Results. The cohort comprised 549 patients: 477 (86.9%) Turkish and 72 (13.1%) Azerbaijani. Azerbaijani patients had earlier symptom onset (30 [IQR 16-67] vs. 48 [IQR: 24–72] months, p=0.044) but a longer diagnostic delay (14 [IQR: 11.4–48.7] vs. 12 [IQR: 6–23] months, p<0.001). Turkish patients showed higher rates of chest pain (22.6% vs. 8.3%, p=0.005), arthralgia (52.6% vs. 32 %, p= 0.001), annual attack frequency (12 [IQR: 6–12] vs. 6 [IQR: 4–8], p<0.001), International Severity Score for Familial Mediterranean Fever (ISSF) scores (2 [IQR: 1–3] vs. 2 [IQR: 1–2], p=0.002), and C-reactive protein (CRP) levels (56 [IQR: 34–96] vs. 17.9 [IQR: 3.2–35.6] mg/L, p<0.001). Confirmatory exon 10 genotypes predominated in Turkish patients (66.7%) whereas unconfirmatory genotypes in Azerbaijani patients (59.7%). M694V was the most common variant in both groups. Within exon 10 homozygotes, Turkish patients had higher ISSF scores (median 3 [IQR: 2–4] vs. 2 [IQR: 1–3], p=0.037) and more arthritis (39% vs 6.3%, p=0.032). Colchicine response was comparable (90.6% vs. 93.1%), but anti–IL-1 use was higher in Turkish patients (11.5% vs. 2.9%, p=0.028). Conclusion. This first systematic Türkiye–Azerbaijan comparison reveals distinct genotype–phenotype correlations in pediatric FMF, with Turkish patients showing a higher burden of confirmatory exon 10 genotypes and more severe disease, highlighting the need for center- and population-aware management strategies.